Financière de Tubize SA Rentabilidad sobre recursos propios
¿Qué es el Rentabilidad sobre recursos propios de Financière de Tubize SA?
El Rentabilidad sobre recursos propios de Financière de Tubize SA es 9.88%
¿Cuál es la definición de Rentabilidad sobre recursos propios?
El rendimiento del capital es una medida de la rentabilidad de una empresa en relación con el valor contable del capital contable. Se calcula dividiendo los ingresos netos del año fiscal por el capital contable total.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Rentabilidad sobre recursos propios de compañías en Sector Health Care en EURONEXT en comparadas con Financière de Tubize SA
¿Qué hace Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Empresas con rentabilidad sobre recursos propios similar a Financière de Tubize SA
- Genesys International tiene Rentabilidad sobre recursos propios de 9.87%
- Generix SA tiene Rentabilidad sobre recursos propios de 9.87%
- ACC tiene Rentabilidad sobre recursos propios de 9.87%
- Navigator Global Investments tiene Rentabilidad sobre recursos propios de 9.87%
- Boiron SA tiene Rentabilidad sobre recursos propios de 9.87%
- Boiron SA tiene Rentabilidad sobre recursos propios de 9.87%
- Financière de Tubize SA tiene Rentabilidad sobre recursos propios de 9.88%
- Sical Logistics tiene Rentabilidad sobre recursos propios de 9.88%
- B.L. Kashyap and Sons tiene Rentabilidad sobre recursos propios de 9.89%
- Xilam Animation SA tiene Rentabilidad sobre recursos propios de 9.89%
- Xilam Animation tiene Rentabilidad sobre recursos propios de 9.89%
- Gillanders Arbuthnot and tiene Rentabilidad sobre recursos propios de 9.89%
- Sodifrance SA tiene Rentabilidad sobre recursos propios de 9.89%